



# Some of the new psychotropic medications 2024-2025

Javier Covas

Ross Medical University School of Medicine

**SPRAVATO®**  
**(esketamine)**

**Spravato™**  
(esketamine)   
nasal spray 



**Indication:**  
Treatment-resistant  
depression (TRD)  
and major  
depressive disorder  
(MDD) with suicidal  
ideation.



**Mechanism:** NMDA  
receptor antagonist,  
rapidly improving  
depressive  
symptoms via  
glutamate  
modulation.



**FDA Approval:** First  
approved in 2019,  
continues to be used  
in 2024.



**What's new?** Now  
comes in Nasal Spray  
Device



**Key Advantage:** Works  
within hours compared to  
traditional antidepressants  
that take weeks.

# Onyda XR (Clonidine)

**ONYDA XR**  
(clonidine HCl) extended-release  
oral suspension 0.1 mg/mL



## **Indication:**

Attention-deficit  
hyperactivity  
disorder (ADHD) for  
6 years and older.



## **Mechanism:**

Extended-release  
stimulant medication  
targeting dopamine  
and norepinephrine.



## **FDA Approval:**

Approved in 2024 as  
a once-daily  
formulation.



**What's great?** New liquid  
formulation, easier for  
children with difficulty  
swallowing pills



**Key Advantage:**  
Improved symptom  
control with once-a-day  
dose.

# Zunveyl (Benzgalantamine)



**Indication:** Mild-to-moderate dementia in Alzheimer's disease.



**Mechanism:** Acetylcholinesterase inhibitor, improving cognitive function by enhancing cholinergic activity.



**FDA Approval:** Approved in July 2024.



**Key Advantage:** Designed to minimize gastrointestinal side effects compared to older acetylcholinesterase inhibitors.

# Kisunla (Donanemab-Azbt)

kisunla™  
(donanemab-azbt)  
injection for IV infusion  
350 mg/20 mL



**Indication:** Early-stage Alzheimer's disease with confirmed amyloid plaques.



**Mechanism:** Monoclonal antibody targeting beta-amyloid plaques, slowing cognitive decline.



**FDA Approval:** Approved in July 2024.



**Key Advantage:** Monthly infusion; first therapy that allows treatment discontinuation once amyloid is cleared.

# Fanapt (Iloperidone)

**Fanapt**<sup>®</sup>  
(iloperidone) tablets  
1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, 12 mg



**Indication:**  
treatment of manic  
or mixed episodes  
associated with  
bipolar I disorder  
and schizophrenia.



**Mechanism:**  
Atypical  
antipsychotic,  
targeting dopamine  
D2 and serotonin 5-  
HT2A receptors.



**FDA Approval:** First  
approved in 2009;  
new formulations in  
2024.



**Key Advantage:** Reduced risk of  
extrapyramidal side effects compared to older  
antipsychotics.

# Cobenfy® (Xanomeline– Trospium)

**COBENFY™**   
(xanomeline and trospium chloride) capsules  
50mg/20mg, 100mg/20mg, 125mg/30mg



**Indication:**  
Schizophrenia in  
adults.



**Mechanism:**  
Muscarinic receptor  
agonist (non–  
dopaminergic).



**FDA Approval:**  
Approved in  
September 2024.



It's a new treatment  
option for patients  
who have struggled  
with conventional  
antipsychotic  
medications.



**Key Advantage:** No direct  
dopamine blockade,  
potentially fewer metabolic  
and movement–related side  
effects.

# Ingrezza Sprinkle (Valbenazine)



**INGREZZA**<sup>®</sup>  
SPRINKLE  
(valbenazine) capsules



**Indication:** Tardive dyskinesia (a movement disorder caused by long-term antipsychotic use).



**Mechanism:** VMAT2 inhibitor, reducing involuntary movements.



**FDA Approval:** Approved in 2024 as a new formulation of Ingrezza.



**Key Advantage:** Sprinkle formulation for easier administration, particularly for patients with swallowing difficulties.

# Citation

- U.S. Food and Drug Administration. (2024). *ONYDA XR (clonidine hydrochloride) extended-release oral suspension: Prescribing Information* (Drug Label 217645). Center for Drug Evaluation and Research. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2024/217645s001](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217645s001)
- Bristol-Myers Squibb. (2024). COBENFY (xanomeline and trospium chloride) [package insert]. Princeton, NJ: Author. [https://packageinserts.bms.com/pi/pi\\_cobenfy.pdf](https://packageinserts.bms.com/pi/pi_cobenfy.pdf)
- U.S. Food and Drug Administration. (2024). KISUNLA (donanemab-azbt) injection: Prescribing information (New Drug Application Approval NDA 218390). U.S. Food and Drug Administration / U.S. Food and Drug Administration.
- Alpha Cognition Inc. (2024). A new approach for the treatment and administration of Alzheimer's disease. <https://www.alphacognition.com/treatments/alzheimers-alpha-1062/>
- Steimel, S. A. (2024, September 5). FDA roundup: Psychiatry Drug Alerts. Psychiatry Advisor. <https://www.psychiatryadvisor.com/features/psychiatry-fda-drug-alerts-2024/#:~:text=The%20Food%20and%20Drug%20Administration,AD%20with%20confir med%20amyloid%20pathology.>
- School, M. M. (2025, January 22). FDA expands approval of intranasal Esketamine Therapy (spravato). Louis A. Faillace, MD, Department of Psychiatry and Behavioral Sciences. [https://med.uth.edu/psychiatry/2025/01/22/fda-expands-approval-of-intranasal-esketamine-therapy-spravato/#:~:text=FDA%20Expands%20Approval%20of%20Intranasal,\(Spravato\)%20% 7C%20McGovern%20Medical%20School](https://med.uth.edu/psychiatry/2025/01/22/fda-expands-approval-of-intranasal-esketamine-therapy-spravato/#:~:text=FDA%20Expands%20Approval%20of%20Intranasal,(Spravato)%20% 7C%20McGovern%20Medical%20School)